Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience

Br J Dermatol. 2019 Jun;180(6):1547-1548. doi: 10.1111/bjd.17580. Epub 2019 Feb 21.
No abstract available

Publication types

  • Letter
  • Multicenter Study

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Dermatologic Agents / administration & dosage*
  • Dermatologic Agents / adverse effects
  • Drug Administration Schedule
  • Drug Substitution
  • Female
  • Humans
  • Injections, Subcutaneous
  • Interleukin-17 / antagonists & inhibitors
  • Interleukin-17 / immunology
  • Male
  • Middle Aged
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • IL17A protein, human
  • Interleukin-17
  • ixekizumab
  • secukinumab